ClinicalTrials.gg
CompletedNCT07237802Updated Oct 30, 2026

Online Pain Neuroscience Education for Women With Primary Dysmenorrhea

An interventional study of PNE online + lifestyle recommendations. and Lifestyle recommendations in Primary Dysmenorrhea (PD), sponsored by Cardenal Herrera University. Completed at 1 site in Spain. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Primary conditionDysmenorrheaRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dysmenorrhea
Why
  1. The study's listed conditions name Dysmenorrhea, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cardenal Herrera University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Dysmenorrhea with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dysmenorrhea · Spain.

Enrollment
8th of 20
82 · median 60
Started
2025
with 1 other
No phase
16 of 23
1 open now
Registered
19th of 23
by date
Lead sponsor
1 of 23
Cardenal Herrera University

Among the 23 studies in Dysmenorrhea with a site in Spain, this one is the 8th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2025, is one of 16 with no phase, and was the 19th registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

3 of the 23 studies in Dysmenorrhea with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 12 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Dysmenorrhea with a site in Spain, or all of them as a file.
02

Study summary

Primary dysmenorrhea is a highly prevalent condition characterized by recurrent menstrual pain in the absence of identifiable pelvic pathology. It affects up to 95% of menstruating women and often interferes with quality of life. Pain neuroscience education (PNE) has shown positive effects in musculoskeletal conditions but has not yet been studied in women with primary dysmenorrhea. This study aims to evaluate the effect of an online PNE intervention combined with lifestyle recommendations, compared to lifestyle recommendations alone

Read the detailed description

This randomized controlled trial will compare an online pain neuroscience education (PNE) program plus lifestyle recommendations with lifestyle recommendations alone in women with primary dysmenorrhea. Participants will be randomized (1:1) to either the intervention group (4-week online PNE modules plus lifestyle recommendations) or the control group (lifestyle recommendations only). The program is based on Butler and Moseley's pain neuroscience principles, adapted to menstrual pain. Outcomes will be assessed at baseline and at 6 months. The primary outcome is pain intensity. Secondary outcomes include anxiety, depression, kinesiophobia and pain catastrophizing,

03

Conditions studied

  • Primary Dysmenorrhea (PD)

Browse trials for

Keywords

  • Pain
  • Dysmenorrhea
  • Kinesiophobia
04

In context

Dysmenorrhea Reclassified

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

This study's enrollment of 82 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.

Browse Dysmenorrhea studies →

Lead sponsor

Cardenal Herrera University is the lead sponsor of 109 studies on the registry; 23 are open to participants now.

Compared within Dysmenorrhea, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Nulliparous women aged 18 to 35 years.
  • Clinical diagnosis of primary dysmenorrhea.
  • History of moderate to severe menstrual pain for at least six consecutive menstrual cycles.
  • Pain intensity score greater than 5 on a numerical rating scale (0-10).
  • No prior use of pain neuroscience education (PNE).
  • No history of pregnancy.

Exclusion criteria

Exclusion Criteria:

  • History of lower abdominal surgery.
  • Presence of severe mental health disorders.
  • Current use of hormonal .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Online Pain Neuroscience Education (PNE)

    Participants in this arm will receive an online pain neuroscience education (PNE) program plus usual lifestyle recommendations. The PNE intervention consists of four weekly audiovisual and written modules adapted to the context of primary dysmenorrhea, focusing on the neurobiology and biopsychosocial aspects of pain, with practical strategies to reduce maladaptive beliefs, kinesiophobia, and catastrophizing.

    Other: PNE online + lifestyle recommendations.

  • Active comparator
    Active Comparator

    Participants in this arm will receive the usual lifestyle recommendations for primary dysmenorrhea. These recommendations include general advice on healthy habits and self-management strategies typically provided in clinical practice.

    Other: Lifestyle recommendations

Interventions

  • OtherPNE online + lifestyle recommendations.

    Four-week online educational program with audiovisual modules on the neurobiology and biopsychosocial aspects of pain, adapted to women with primary dysmenorrhea. In addition, participants receive usual lifestyle recommendations, including general advice on healthy habits and self-management strategies commonly provided in clinical practice.

  • OtherLifestyle recommendations

    Participants in this arm will receive online lifestyle recommendations for four weeks, including general advice on healthy habits and self-management strategies commonly provided in clinical practice for women with primary dysmenorrhea.

07

What researchers measure

Primary outcomes

  1. Pain intensity measured by the 11-point Numeric Rating Scale (NRS)

    Pain intensity will be assessed using the 11-point Numeric Rating Scale (NRS). Participants will rate their average menstrual pain intensity over the previous cycle, from 0 ("no pain") to 10 ("worst imaginable pain"). Higher scores indicate greater pain intensity.

    Time frame: pre-intervention and 6 months post-intervention

Secondary outcomes

  1. Anxiety and depression measured by the Hospital Anxiety and Depression Scale (HADS)

    The Hospital Anxiety and Depression Scale (HADS) has 14 items, with two subscales: HADS-Anxiety (7 items) and HADS-Depression (7 items). Each subscale ranges 0-21; higher scores indicate greater anxiety/depression.

    Time frame: pre-intervention and 6 months post-intervention

  2. Kinesiophobia measured by the Tampa Scale for Kinesiophobia-11 (TSK-11)

    The Tampa Scale for Kinesiophobia-11 (TSK-11) has 11 items scored 1 ("strongly disagree") to 4 ("strongly agree"). Total score 11-44; higher scores indicate greater fear of movement/re-injury.

    Time frame: pre-intervention and 6 months post-intervention

  3. Pain catastrophizing measured by the Pain Catastrophizing Scale (PCS)

    The Pain Catastrophizing Scale (PCS) includes 13 items scored 0 ("not at all") to 4 ("all the time"). Total score 0-52; higher scores indicate greater pain catastrophizing.

    Time frame: pre-intervention and 6 months post-intervention

08

Study locations

1 site
  • Universidad CEU Cardenal Herrera
    Valencia, Valencia-valència 46006, Spain
09

References and documents

Publications

  • Soderman L, Edlund M, Marions L. Prevalence and impact of dysmenorrhea in Swedish adolescents. Acta Obstet Gynecol Scand. 2019 Feb;98(2):215-221. doi: 10.1111/aogs.13480. Epub 2018 Nov 6. PubMed 30312470 ↗
  • Butler DS, Moseley GL. Explain Pain. 2nd ed. Adelaide, South Australia: Noigroup Publications; 2013.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in May 2026, 7 months.

Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 7 months is below that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Sep 2025 → Oct 2025, primary completion Feb 2026 → May 2026 and completion Feb 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Nov 20, 2025
StartActual
Oct 10, 2025was Sep 2025
Primary completionActual
May 28, 2026was Feb 2026
CompletionActual
May 28, 2026was Feb 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2025→Oct 10, 2025
Oct 30, 2026
Primary completion
Feb 28, 2026→May 28, 2026
Oct 30, 2026
Study completion
Feb 28, 2026→May 28, 2026
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Start date Sep 1, 2025→Oct 10, 2025
    Primary completion Feb 28, 2026→May 28, 2026
    Study completion Feb 28, 2026→May 28, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07237802
Responsible party
Juan F. Lisón Párraga, Dr (Dr, Cardenal Herrera University) — Principal investigator
First posted
Nov 20, 2025
Start date
Oct 10, 2025
Primary completion
May 28, 2026
Completion
May 28, 2026
Last update
Oct 30, 2026

Study contacts

Juan Francisco Lisón Párraga, Dr
principal investigator · Universidad Cardenal Herrera CEU

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion